JP6756617B2 - Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法 - Google Patents

Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法 Download PDF

Info

Publication number
JP6756617B2
JP6756617B2 JP2016551712A JP2016551712A JP6756617B2 JP 6756617 B2 JP6756617 B2 JP 6756617B2 JP 2016551712 A JP2016551712 A JP 2016551712A JP 2016551712 A JP2016551712 A JP 2016551712A JP 6756617 B2 JP6756617 B2 JP 6756617B2
Authority
JP
Japan
Prior art keywords
compound
cancer
crystalline solid
solid form
xxx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016551712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505796A (ja
JP2017505796A5 (enExample
Inventor
ダナ ティー． アフターブ，
ダナ ティー． アフターブ，
ネイサン グズ，
ネイサン グズ，
スティーブン ラウ，
スティーブン ラウ，
ノエル ハミル，
ノエル ハミル，
トレーシー ウォーカー，
トレーシー ウォーカー，
ジャナ ガルブレイス，
ジャナ ガルブレイス，
サイモン ヤオ，
サイモン ヤオ，
ハリド シャー，
ハリド シャー，
Original Assignee
エグゼリクシス， インコーポレイテッド
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド, エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2017505796A publication Critical patent/JP2017505796A/ja
Publication of JP2017505796A5 publication Critical patent/JP2017505796A5/ja
Application granted granted Critical
Publication of JP6756617B2 publication Critical patent/JP6756617B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016551712A 2014-02-14 2015-02-16 Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法 Active JP6756617B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461939985P 2014-02-14 2014-02-14
US61/939,985 2014-02-14
PCT/US2015/016052 WO2015123639A1 (en) 2014-02-14 2015-02-16 Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019125128A Division JP2019163337A (ja) 2014-02-14 2019-07-04 Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法

Publications (3)

Publication Number Publication Date
JP2017505796A JP2017505796A (ja) 2017-02-23
JP2017505796A5 JP2017505796A5 (enExample) 2019-01-31
JP6756617B2 true JP6756617B2 (ja) 2020-09-16

Family

ID=52684662

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016551712A Active JP6756617B2 (ja) 2014-02-14 2015-02-16 Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法
JP2019125128A Pending JP2019163337A (ja) 2014-02-14 2019-07-04 Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019125128A Pending JP2019163337A (ja) 2014-02-14 2019-07-04 Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法

Country Status (14)

Country Link
US (5) US10501418B2 (enExample)
EP (2) EP3105204A1 (enExample)
JP (2) JP6756617B2 (enExample)
KR (1) KR102354963B1 (enExample)
CN (1) CN106068255A (enExample)
AU (3) AU2015218236B2 (enExample)
BR (1) BR112016018450A2 (enExample)
CA (2) CA3181899A1 (enExample)
EA (1) EA032757B1 (enExample)
IL (1) IL247035B2 (enExample)
MX (2) MX384828B (enExample)
UA (1) UA123534C2 (enExample)
WO (1) WO2015123639A1 (enExample)
ZA (1) ZA201605424B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
GEP20196995B (en) 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
CN106255499A (zh) 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
MA40457A (fr) 2014-08-05 2017-06-14 Exelixis Inc Combinaison de médicaments pour traiter le myélome multiple
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018104954A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
UA126970C2 (uk) * 2017-01-20 2023-03-01 Екселіксіс, Інк. Комбінації кабозантинібу і атезолізумабу для лікування раку
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
MX2019012505A (es) * 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
US11504362B2 (en) 2017-06-09 2022-11-22 Exelixis, Inc. Liquid dosage forms to treat cancer
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN107951850A (zh) * 2017-12-20 2018-04-24 深圳万乐药业有限公司 一种苹果酸卡博替尼片的制备方法
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
PL3894012T4 (pl) 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
WO2022177983A1 (en) 2021-02-19 2022-08-25 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
KR20250136810A (ko) 2023-01-31 2025-09-16 한다 온콜로지, 엘엘씨 개선된 카보잔티닙 조성물 및 사용 방법
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
WO2006108059A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
CA2743416A1 (en) 2008-11-13 2010-05-20 Exelixis Inc. Methods of preparing quinoline derivatives
US20130030172A1 (en) 2008-12-04 2013-01-31 Exelixis, Inc. Methods of Preparing Quinoline Derivatives
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
BR112012001118A2 (pt) 2009-07-17 2016-02-23 Exelixis Inc formas cristalinas de n-[3-flúor-4-({6-(metilóxi)-7-[(3-morfolin-4-ilpropil)óxi]-quinolin-4-il}óxi)fenil]-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composição farmacêutica com as mesmas, métodos de preparação das mesmas e tratamento de câncer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EA201290906A1 (ru) 2010-03-12 2013-03-29 Экселиксис, Инк. Кристаллогидратные формы n-[3-фтор-4-({6-(метилокси)-7-[(3-морфолин-4-илпропил)окси]хинолин-4-ил}окси)фенил]-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2012009722A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP2621482A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
US20130252956A1 (en) 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
TW201309650A (zh) 2011-02-10 2013-03-01 艾克塞里克斯公司 製造喹啉化合物之方法及包含該化合物之醫藥組合物
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
EP2704717A1 (en) 2011-05-02 2014-03-12 Exelixis, Inc. Method of treating cancer and bone cancer pain
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
PL2768796T3 (pl) 2011-10-20 2020-05-18 Exelixis, Inc. Sposób wytwarzania pochodnych chinoliny
US9535315B2 (en) 2011-10-31 2017-01-03 Applied Materials, Inc. Method of fabricating a color filter array using a multilevel structure
MX2014005458A (es) 2011-11-08 2015-04-16 Exelixis Inc Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.
WO2013070903A1 (en) 2011-11-08 2013-05-16 Exelixis, Inc. Method of quantifying cancer treatment
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
JP6513567B2 (ja) 2012-09-07 2019-05-15 エクセリクシス， インク． 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
CN103664776B (zh) 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
GEP20196995B (en) 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
EP2983639A1 (en) 2013-04-04 2016-02-17 Exelixis, Inc. Drug combinations to treat cancer
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
CN104370811B (zh) 2013-08-15 2019-02-12 广东东阳光药业有限公司 一种喹啉化合物的新晶型及其制备方法
CN103664778B (zh) 2013-11-27 2017-04-05 苏州摩尔医药有限公司 一种抗肿瘤治疗药物卡博替尼的合成方法
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
CN106255499A (zh) 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
MA40457A (fr) 2014-08-05 2017-06-14 Exelixis Inc Combinaison de médicaments pour traiter le myélome multiple
WO2016061253A1 (en) 2014-10-14 2016-04-21 Exelixis, Inc. Drug combination to treat melanoma
MX2019012505A (es) * 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.

Also Published As

Publication number Publication date
EA032757B1 (ru) 2019-07-31
AU2015218236B2 (en) 2019-06-13
CN106068255A (zh) 2016-11-02
US12486233B2 (en) 2025-12-02
CA2939546C (en) 2023-01-17
JP2019163337A (ja) 2019-09-26
MX2016010266A (es) 2017-02-08
US20230382867A1 (en) 2023-11-30
EP3105204A1 (en) 2016-12-21
CA3181899A1 (en) 2015-08-20
AU2021204278B2 (en) 2023-10-26
ZA201605424B (en) 2022-12-21
AU2015218236A1 (en) 2016-09-15
KR102354963B1 (ko) 2022-01-21
AU2019226302A1 (en) 2019-09-26
AU2019226302B2 (en) 2021-04-01
CA2939546A1 (en) 2015-08-20
US20210206722A1 (en) 2021-07-08
US20210198205A1 (en) 2021-07-01
AU2021204278A1 (en) 2021-07-22
US11724986B2 (en) 2023-08-15
JP2017505796A (ja) 2017-02-23
MX384828B (es) 2025-03-14
US10851061B2 (en) 2020-12-01
EP3738952A1 (en) 2020-11-18
WO2015123639A1 (en) 2015-08-20
NZ723714A (en) 2021-03-26
IL247035B2 (en) 2023-03-01
US20170044106A1 (en) 2017-02-16
BR112016018450A2 (pt) 2018-09-18
US20200190033A1 (en) 2020-06-18
US10501418B2 (en) 2019-12-10
IL247035B (en) 2022-11-01
UA123534C2 (uk) 2021-04-21
US11760726B2 (en) 2023-09-19
IL247035A0 (en) 2016-09-29
KR20160121544A (ko) 2016-10-19
EA201691629A1 (ru) 2016-11-30
MX2021001583A (es) 2023-02-08

Similar Documents

Publication Publication Date Title
US12486233B2 (en) Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
JP2017505796A5 (enExample)
JP7437460B2 (ja) Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
JP5934204B2 (ja) Ｃ−ｍｅｔ調節剤の薬学的組成物
JP2012533570A (ja) Ｎ−［３−フルオロ−４−（｛６−（メチルオキシ）−７−［（３−モルホリン−４−イルプロピル）オキシ］−キノリン−４−イル｝オキシ）フェニル］−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶形
HK40040786A (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
NZ723714B2 (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
HK40020497A (en) Crystalline solid forms of salts, processes for making, and methods of use
HK40020497B (en) Crystalline solid forms of salts, processes for making, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200217

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200811

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200827

R150 Certificate of patent or registration of utility model

Ref document number: 6756617

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250